Finally, mTORC1 inhibition by CRG improves NAFLD in vivo and activates PPARα to reduce fat accumulation, followed by M2 polarization in Raw264.7 cells in vitro. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.